All In Biotech

Drug Trial Radar · NCT04119843

Safety and Diagnostic Efficacy of Mangoral in Participants With Focal Liver Lesions and Reduced Kidney Function

A Multicenter, Open-label Study to Evaluate the Safety and Diagnostic Efficacy of Mangoral in Patients With Known or Suspected Focal Liver Lesions and Severe Renal Impairment

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

87

Actual

Start

Feb 19, 2020

Primary completion

Feb 17, 2023

Study completion Feb 17, 2023

Sponsor

Lead sponsor
Ascelia Pharma ABIndustry
Sponsor type
Industry
First posted
Oct 8, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The overall objective of this study is to evaluate the safety and diagnostic efficacy of Mangoral in liver MRI in participants with known or suspected focal liver lesions and severe renal impairment. The diagnostic efficacy of Mangoral will be assessed in terms of visualization of detected focal liver lesions in combined MRI (CMRI: combined Mangoral-enhanced and unenhanced MRI) compared to unenhanced MRI.

Conditions

  • Known or Suspected Focal Liver Lesions
  • Severe Renal Impairment

Interventions

  • MangoralDrug

    800 mg manganese chloride \[II\] tetrahydrate, 500 mg L-alanine, and 800 IU vitamin D3

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Co-primary Endpoint: Lesion Border Delineation in Combined MRI Compared to Unenhanced MRITime frame: Unenhanced MRI: Baseline Period (Day -1 to Day 0); combined MRI: Baseline Period (Day -1 to Day 0) and 4 hours after mangoral administration on Day 0
  2. Co-primary Endpoint: Lesion Contrast in Combined MRI Compared to Unenhanced MRITime frame: Unenhanced MRI: Baseline Period (Day -1 to Day 0); combined MRI: Baseline Period (Day -1 to Day 0) and 4 hours after mangoral administration on Day 0

Locations

60 sites in 10 countries. Site status is shown where the registry gives one.

  • Mayo Clinic - Arizona

    Scottsdale, Arizona

  • University of California at Los Angeles Ronald Reagan Medical Center

    Los Angeles, California

  • Stanford University School of Medicine

    Stanford, California

  • Mayo Clinic - Jacksonville

    Jacksonville, Florida

  • Schiff Center for Liver Diseases

    Miami, Florida

  • University of Kansas Medical Center

    Kansas City, Kansas

  • Johns Hopkins Bayview Medical Center

    Baltimore, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Boston University Medical Center

    Boston, Massachusetts

  • Saint Louis University

    St Louis, Missouri

  • Duke University

    Durham, North Carolina

  • PanAmerican Clinical Research LLC

    Brownsville, Texas

  • University of Washington Medical Center

    Seattle, Washington

  • University of Wisconsin - Madison

    Madison, Wisconsin

  • Centro Rossi Body Imaging

    Buenos Aires, Argentina

  • Sanatorio Allende Nueva Córdoba

    Córdoba, Argentina

  • Fundación Intecnus

    Bariloche, Río Negro Province, Argentina

  • Hospital Pablo Tobon Uribe

    Medellín, Antioquia, Colombia

  • Clínica Universitaria Colombia

    Bogotá, Cundinamarca, Colombia

  • Sociedad de Cirugía de Bogotá - Hospital de San José

    Bogotá, Cundinamarca, Colombia

  • Charité - Universitätsmedizin Berlin

    Berlin, Germany

  • Universitätsklinikum Frankfurt Institut für Diagnostische und Interventionelle Radiologie

    Frankfurt, Germany

  • Universitätsmedizin Göttingen

    Göttingen, Germany

  • Städtisches Klinikum KarlsruheDiagnostische und interventionelle Radiologie

    Karlsruhe, Germany

  • Universitättsklinikum Schleswig-Holstein/Campus KielKlinik für Radiologie und Neuroradiologie

    Kiel, Germany

  • Klinik und Poliklinik für Radiologie Klinikum der Universität München LMU Campus

    Munich, Germany

  • Institut für Röntgendiagnostik

    Regensburg, Germany

  • Azienda Ospedaliero-Universitaria di Bologna Policlinico S.Orsola-Malpighi

    Bologna, Italy

  • Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda

    Milan, Italy

  • Ospedale del Mare

    Naples, Italy

  • Istituto Nazionale Tumori IRCCS Fondazione G. Pascale

    Naples, Italy

  • Università Cattolica del Sacro Cuore

    Roma, Italy

  • Azienda Ospedaliero-Universitaria Policlinico Umberto I

    Rome, Italy

  • Ospedale di Belcolle

    Viterbo, Italy

  • Azienda Socio Sanitaria Territoriale (ASST)

    Milan, Lombardy, Italy

  • Panamerican Clinical Research - Cuernavaca Rio Mayo

    Cuernavaca, Mexico

  • Panamerican Clinical Research Mexico

    Guadalajara, Mexico

  • Panamerican Clinical Research - Querétaro Avenida Paseo de la República

    Querétaro, Mexico

  • Szpital Uniwersytecki nr 1 im. Dr A. Jurasza, Wydział Katedra i Zakład Radiologii i Diagnostyki Obrazowej

    Bydgoszcz, Poland

  • Szpital Uniwersytecki w Krakowie Zakład Diagnostyki Obrazowej CUMRiK Ul

    Krakow, Poland

Showing 40 of 60 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.